Clinical Trials Browser

INDUSTRY × Neoplasm Metastasis × Albumin-Bound Paclitaxel × Clear all

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT05669482 2025-09-02

RAMP205

Phase 1/2 Active not recruiting

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT05586516 2025-03-20

A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Fibrosis, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04983407 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Phase 1/2 Terminated

Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Unknown

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT02799862 2021-10-06

NEPTUN

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02045602 2020-10-08

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Phase 1 Completed

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02715804 2020-07-14

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Phase 3 Terminated

492 enrolled 16 charts

Gastrointestinal

Neoplasm Metastasis, Carcinoma, Pancreatic Ductal

NCT02077881 2020-05-28

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Neoplasm Metastasis

NCT02559674 2020-01-27

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

Phase 1 Completed

Neoplasm Metastasis, Neoplasms

NCT00140140 2019-11-26

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Phase 1/2 Terminated

16 enrolled 21 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00281528 2019-11-22

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Phase 2 Terminated

208 enrolled 23 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Phase 1 Terminated

BreastGastrointestinalLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

NCT00093119 2017-04-26

Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma, Neoplasm Metastasis

NCT00046514 2016-12-15

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00046423 2016-11-25

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Phase 1 Completed

Neoplasm Metastasis, Neoplasms

NCT00046527 2006-07-13

Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms, Neoplasm Metastasis